Icahn Enterprises IEP Pharma — Cost Of Goods Sold New
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept iep:CostOfGoodsSoldNew.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — cost of goods sold new.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — cost of goods sold new?
- Icahn Enterprises (IEP) reported pharma — cost of goods sold new of $9M in Q1 2026.
- How has Icahn Enterprises's pharma — cost of goods sold new changed year-over-year?
- Icahn Enterprises's pharma — cost of goods sold new decreased by 30.8% year-over-year, from $13M to $9M.
- What is the long-term trend for Icahn Enterprises's pharma — cost of goods sold new?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — cost of goods sold new has grown at a 4.7% compound annual growth rate (CAGR), from $50M to $60M.
- What does pharma — cost of goods sold new mean?
- The direct costs attributable to the production and manufacturing of pharmaceutical products sold during the period. Monitoring this metric is essential for evaluating the segment's production efficiency and gross margin management.